Keywords: irbesartan, cleared, diabetic, renal, disease, europe, sanofi-synthelabo
Irbesartan cleared for diabetic renal disease in Europe
Article | 01 July 2002
Sanofi-Synthelabo's angiotensin II receptor antagonist Aprovel/Karvea(irbesartan) has been approved for a new indication in the European Union, namely ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
